source
- LifeMine Therapeutics secures $263 million in dual venture rounds to advance organ transplant aftercare drugLifeMine Therapeutics announced it has raised a total of $263 million through a $75 million Series D and an $188 million Series F round, opting for private financing rather than an IPO. The capita…
- Tarsus to acquire Alkeus for $450 million, adding phase-3 retinal drug and oral Stargardt candidateTarsus Pharmaceuticals announced it will buy Alkeus Pharmaceuticals in a transaction valued at $450 million. The deal consists of $270 million in cash and $180 million of Tarsus common stock, givi…